NILO Therapeutics
Nilo Therapeutics is a biotechnology company launched to develop medicines that target neural circuits to treat immune diseases. The company announced a $101 million Series A financing and the appointment of Kim Seth as CEO to advance a pipeline of neuro-immune therapeutics.
Industries
Nr. of Employees
small (1-50)
Products
Pipeline of medicines targeting neural circuits in immune disease
A pipeline of therapeutic candidates designed to treat immune-mediated diseases by modulating specific neural circuits that influence immune responses.
Pipeline of medicines targeting neural circuits in immune disease
A pipeline of therapeutic candidates designed to treat immune-mediated diseases by modulating specific neural circuits that influence immune responses.
Expertise Areas
- Neuroimmunology
- Therapeutic discovery and development
- Translational R&D
- Biotech fundraising and company formation
Key Technologies
- Neuroimmune modulation
- Targeted therapeutic development
- Preclinical models for immune disease
- Drug discovery platforms
News & Updates
Announcement of company launch with $101 million Series A financing and appointment of Kim Seth as CEO to advance medicines targeting neural circuits in immune disease.
Raised $101 million in Series A funding to launch the company and advance a pipeline of neuro-immune medicines.
Kim Seth appointed as Chief Executive Officer at company launch.
Announcement of company launch with $101 million Series A financing and appointment of Kim Seth as CEO to advance medicines targeting neural circuits in immune disease.
Raised $101 million in Series A funding to launch the company and advance a pipeline of neuro-immune medicines.
Kim Seth appointed as Chief Executive Officer at company launch.